Equities

SINTX Technologies Inc

SINTX Technologies Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)4.98
  • Today's Change-0.29 / -5.50%
  • Shares traded4.00
  • 1 Year change-98.41%
  • Beta1.4671
Data delayed at least 15 minutes, as of Jul 29 2024 20:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

SINTX Technologies, Inc. is an advanced ceramics company. The Company is focused on providing solutions in a variety of biomedical, technical, and antipathogenic applications. The Company is focusing primarily on the research, development and commercialization of medical devices manufactured with silicon nitride. The Company is manufacturing, research, and development of products comprised from advanced ceramic materials for external partners. It produces silicon nitride for use in its commercial products and product candidates in various forms: solid silicon nitride, porous silicon nitride, silicon nitride powder, composites of silicon nitride and PEEK and PEKK and silicon nitride coating. It is also focused on development and manufacturing ceramics for personnel, aircraft, and vehicle armor. Its silicon nitride products can be polished to a smooth and wear-resistant surface for articulating applications, such as bearings for hip and knee replacements.

  • Revenue in USD (TTM)2.78m
  • Net income in USD-8.88m
  • Incorporated1996
  • Employees43.00
  • Location
    SINTX Technologies Inc1885 West 2100 StreetSALT LAKE CITY 84119United StatesUSA
  • Phone+1 (801) 839-3516
  • Fax+1 (801) 839-3605
  • Websitehttps://sintx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Nuwellis Inc8.90m-19.93m3.18m59.00--21.83--0.358-8.30-8.302.730.13040.70761.557.04150,762.70-143.62-98.07-216.07-122.4857.4155.22-202.97-230.510.7092-4.750.00--3.7612.14-55.78--4.61--
Therapeutic Solutions International Inc97.68k-2.18m3.21m3.00--2.10--32.90-0.0006-0.00060.000030.00030.02571.305.4432,560.00-63.47-162.32-172.17--63.3667.79-2,468.37-2,391.850.4652-6.420.2868---52.1395.3543.11------
Invo Bioscience Inc4.25m-7.08m3.28m25.00------0.7714-5.68-5.682.590.00390.34739.5030.72169,953.20-57.87-94.63-128.00-151.4539.9074.91-166.64-343.110.1629-5.860.9965--267.3843.6226.24--87.09--
Fuse Medical Inc18.40m3.63m3.33m31.001.25--0.90160.18070.0360.0360.2307-0.00310.95930.70185.75593,671.9018.910.750448.451.3564.9554.9819.720.65520.3143-1.131.12---8.67-6.72295.1134.66----
Bioelectronics Corp1.61m-289.82k3.46m9.00------2.15-0.00002-0.000020.00007-0.00066.329.2014.53---113.86-383.59----49.4351.48-18.01-143.480.0099-0.4909----94.01-5.0975.01------
Optimus Healthcare Services Inc1.57m-8.57m3.53m12.00------2.25-0.2139-0.21390.039-0.18840.9263--3.12130,884.20-505.59------83.03---545.81-----7.49----22.88---3.51------
Arch Therapeutics Inc130.55k-8.43m3.56m8.00------27.23-3.68-3.680.0425-2.450.08330.0637--16,318.75-538.25-188.28---804.6333.37---6,458.14-26,945.920.0164-1.27----383.83---32.35---21.76--
ADM Tronics Unlimited Inc2.97m-877.23k3.72m7.00--5.38--1.26-0.013-0.0130.04390.01021.134.897.04---33.56-15.22-58.66-22.0937.6541.15-29.58-18.580.8015-316.560.4233---19.35-0.3572-810.74------
SINTX Technologies Inc2.78m-8.88m3.73m43.00--0.013--1.34-389.94-389.9474.21383.240.1381.625.8464,534.88-44.03-45.71-57.11-57.3667.9658.47-318.99-681.801.67--0.0229--68.2994.2449.75--54.10--
Applied DNA Sciences Inc5.52m-12.50m3.80m53.00------0.6892-17.13-17.137.67-0.05580.389310.384.64104,110.80-87.15-88.57-111.09-121.9133.9844.35-223.89-113.261.54-------26.4327.92-18.73--33.80--
AccuStem Sciences Inc0.00-1.74m3.90m3.00---------0.1537-0.15370.00-0.23090.00----0.00-1,168.46--------------------------45.26------
Encision Inc6.59m-691.78k4.04m22.00--2.21--0.6129-0.0588-0.05880.55950.1541.662.097.27299,357.70-17.41-3.03-24.73-4.1347.6251.25-10.50-1.890.8393-10.270.1272---10.38-5.64-113.55---9.54--
Tivic Health Systems Inc1.13m-7.61m4.34m9.00--0.4805--3.83-11.17-11.171.021.460.21840.923717.31126,000.00-146.51---194.55--30.07---670.99--2.07--0.00---36.09--18.34------
Nu-Med Plus Inc0.00-119.16k4.39m2.00---------0.0014-0.00140.00-0.0020.00----0.00-350.01-447.69---------------22.74--------3.56------
Dror Ortho-Design Inc0.00-4.83m4.46m4.00--1.87-----0.0115-0.01150.000.00480.00-------357.10-140.50-595.21---------118,188.00----0.00-------1,896.02------
Data as of Jul 29 2024. Currency figures normalised to SINTX Technologies Inc's reporting currency: US Dollar USD

Institutional shareholders

4.62%Per cent of shares held by top holders
HolderShares% Held
L1 Capital Global, Inc.as of 25 Mar 202422.50k3.67%
Anson Funds Management LPas of 31 Mar 20244.80k0.78%
Two Sigma Securities LLCas of 31 Mar 2024424.000.07%
The Vanguard Group, Inc.as of 31 Mar 2024217.000.04%
Geode Capital Management LLCas of 31 Mar 2024109.000.02%
HRT Financial LLCas of 31 Mar 202490.000.02%
SSgA Funds Management, Inc.as of 31 Mar 202486.000.01%
Kestra Private Wealth Services LLCas of 31 Mar 202450.000.01%
Tower Research Capital LLCas of 31 Mar 202447.000.01%
Morgan Stanley & Co. LLCas of 31 Mar 202411.000.00%
More ▼
Data from 31 Mar 2024 - 27 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.